Founder, Chief Scientific Officer

Dr. Bally is Head and Distinguished Scientist of the Department of Experimental Therapeutics at the BC Cancer. As an independent researcher with experience in academia and industry, he has focused his career on development of much needed novel drugs, drug combinations and drug delivery systems designed for use in patients with metastatic cancer. He has generated over 550 scientific articles, abstracts, book chapters and patents that have been cited over 17,400 times. He has been a PI/Co-PI on grants valued at over $50M and he has participated in private sector funding for companies that he co-founded (Lipex, Inex (now Arbutus), Northern Lipids (renamed Transferra and purchased by Evonik in 2016), Celator (purchased by Jazz in 2016 for $1.4 billion) and most recently Cuprous Pharmaceuticals. This effort resulted in three approved drugs: Myocet®- for metastatic breast cancer, Marqibo®- for relapsed ALL, and CPX-351 (VYXEOS™) which some believe will replace the standard of care for high risk AML.